This work is licensed under a Creative Commons Attribution 4.0 International License.
E-[c(RGDfK)2]
General Information
DRACP ID DRACP05898
Peptide Name E-[c(RGDfK)2]
Sequence E(RGDfK)(RGDfK)
Sequence Length 11
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Cancer targeted peptides Antiangiogenic αvβ3 Inhibitor
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| U87 | Glioblastoma | Blastoma | IC50=2.5 μM | MTT assay | 72 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HUVEC: IC50=400 nM
Target αvβ3
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Cyclic
Disulfide/Other Bond NCB: Arg1<--->Lys5
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral Mix
Physicochemical Information
Formula C41H69N17O14
Absent amino acids ACFHILMNPQSTVWY
Common amino acids DGKR
Mass 120265
Pl 9.53
Basic residues 4
Acidic residues 3
Hydrophobic residues 0
Net charge 1
Boman Index -6331
Hydrophobicity -255.45
Aliphatic Index 0
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 2
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Development of PEGylated doxorubicin-E-[c(RGDfK)2] conjugate for integrin-targeted cancer therapy
Doi 10.1002/pat.1731
Year 2010
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.